Human apolipoprotein B100 (ApoB100) monoclonal antibody and chemiluminescence immune assay determination kit adopting the human ApoB100 monoclonal antibody

A monoclonal antibody, apolipoprotein technology, applied in the biological field, can solve the problems of long-term storage, false positives, false negatives, etc., and achieve the effects of improved sensitivity, low production cost, and wide detection range
CN102943066BActive Publication Date: 2014-12-03大庆麦伯康生物技术有限公司 +2
1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
大庆麦伯康生物技术有限公司
Publication Date
2014-12-03

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a chemiluminescence immune assay determination kit adopting a human apolipoprotein B100 (ApoB100) monoclonal antibody and a preparation method thereof. The invention also provides the human ApoB100 monoclonal antibody which can specifically recognize human ApoB100, a hybrid tumor for producing the human ApoB100 monoclonal antibody, and a method for high-sensitivity detection of human ApoB100 by the human ApoB100 monoclonal antibody. The chemiluminescence immune assay determination kit has high sensitivity, a wide detection scope and a low cost and is convenient for operation.
Need to check novelty before this filing date? Find Prior Art

Description

【Technical field】

[0001] The present invention relates to the identification of human apolipoprotein B 100 (Apo B 100 ), a hybridoma producing the monoclonal antibody, a Chemiluminescent Immunoassay Quantitative Assay (CLIA) kit and a preparation method thereof, the invention belongs to the field of biotechnology. 【Background technique】

[0002] Cardiovascular and cerebrovascular disease is a common disease that seriously threatens the health of human beings, especially middle-aged and elderly people over 50 years old. The number of people who die from cardiovascular and cerebrovascular diseases in the world is as high as 15 million every year, ranking first among various causes of death. Cardiovascular and cerebrovascular diseases have the characteristics of "high morbidity, high disability rate, high mortality, high recurrence rate, and many complications", that is, "four highs and one high". At present, there are more than 270 million patients with cardiovascular and cer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More